Merck & Co., Inc.MRK

Market cap
$251.9B
P/E ratio
2010/122011/122012/122013/122014/122015/122016/122017/122018/122019/122020/122021/122022/122023/122024/12
Depreciation & amortization7,3817,4276,9786,9886,6916,3755,4414,6374,5193,652-----
Stock-based compensation509369335276278299300312348417475479541645761
Cash from operations 10,82212,38310,02211,6547,86012,42110,3766,44710,92213,44010,25313,12219,09513,00621,468
Capital expenditures-1,678-1,723-1,954-1,548-1,317-1,283-1,614-1,888-2,615-3,473-4,684-4,448-4,388-3,863-3,372
Cash from investing -3,497-2,890-6,805-3,148-374-4,758-3,2102,6794,314-2,629-9,443-16,421-4,960-14,083-7,734
Repurchases of common stock1,5931,9212,5916,5167,7034,1863,4344,0149,0914,7801,281840-1,3461,306
Proceeds from issuance of term debt, net1,999-2,5626,4673,1467,9381,079--4,9584,4197,936-5,939-
Repayments of term debt1,3411,547221,7756,6172,9062,3861,1034,287-1,9572,3192,2511,7551,290
Cash from financing -5,441-6,904-3,267-5,990-15,113-5,270-9,044-10,006-13,160-8,861-2,8323,097-9,119-4,810-7,032
Free cash flow
FCF margin (%)